EUVIMEDEUVIMED entdecken
Crossref

Predicting drugs for epilepsy using genetic and genomic data

Basel A. Taweel

University of Liverpool · 01.01.2023

DOI: 10.17638/03151366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift University of Liverpool, erschienen am 01.01.2023. Verfasst von Basel A. Taweel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

65 million people have epilepsy. Current antiepileptic drugs produce adverse effects in 88% of users and fail to prevent seizures in 30% of people with epilepsy. New drugs for epilepsy are therefore required. Traditional drug development methods are arduous and expensive, taking on average 10-15 years and $2.6 billion per drug. It is estimated that over 90% of drugs have a viable second indication and thus may be used for other purposes, making drug repurposing an attractive alternative. This thesis aims to create drug repurposing resources for epilepsy and generate drug predictions for both monogenic and polygenic epilepsies. We create and present the Seizure Associated Genes Across Species (SAGAS) database, the largest and most comprehensive existing database of epilepsy genes, containing over 9700 pieces of published evidence for the involvement of 3879 genes in the generation and potentiation of seizures across 6 species. We use genetic data from the SAGAS, alongside a publicly available network-based method of drug prediction, to generate drug prediction lists for polygenic focal and generalised epilepsies. A monogenic epileptic syndrome is caused by a single mutant gene. However, knowing the identity of the mutant gene underlying a monogenic epileptic syndrome is not sufficient for predicting the effect of antiseizure medications on the syndrome. Dravet syndrome (DS), the archetypal monogenic epileptic encephalopathy, is typically caused by mutations in SCN1A. Some antiseizure medications that alleviate seizures in Dravet syndrome do not affect SCN1A, whilst some antiseizure medications that affect SCN1A aggravate seizures in Dravet syndrome. We are not aware of any genomics-based methods that can correctly predict the varying effects of different antiseizure medications on Dravet syndrome (or any other monogenic epileptic syndrome). We create a novel method to predict drugs for Dravet syndrome that takes into account not only the gene that causes Dravet syndrome but also other genes that can influence the expression of its phenotype and show that our predictions correctly identify the antiseizure drugs that are effective, aggravating and equivocal for Dravet syndrome.

Schlagwörter

epilepsydrug repurposingantiepileptic drugsDravet syndromeSCN1Amonogenic epilepsydrug predictiongene expression networksadverse drug reactionsfocal epilepsy

Zitieren

APA

Taweel, B. A. (2023). Predicting drugs for epilepsy using genetic and genomic data. University of Liverpool. https://doi.org/10.17638/03151366

Vancouver

Taweel BA. Predicting drugs for epilepsy using genetic and genomic data. University of Liverpool. 2023. doi:10.17638/03151366

BibTeX
@article{Taweel2023,
  author = {Taweel, Basel A.},
  title = {Predicting drugs for epilepsy using genetic and genomic data},
  journal = {University of Liverpool},
  year = {2023},
  doi = {10.17638/03151366}
}
Kostenlos starten →